TN2013000387A1 - T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 - Google Patents

T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2

Info

Publication number
TN2013000387A1
TN2013000387A1 TNP2013000387A TN2013000387A TN2013000387A1 TN 2013000387 A1 TN2013000387 A1 TN 2013000387A1 TN P2013000387 A TNP2013000387 A TN P2013000387A TN 2013000387 A TN2013000387 A TN 2013000387A TN 2013000387 A1 TN2013000387 A1 TN 2013000387A1
Authority
TN
Tunisia
Prior art keywords
antibodies
hla
conjugates
chimeric
leukemia
Prior art date
Application number
TNP2013000387A
Other languages
French (fr)
Inventor
David A Scheinberg
Tao Dao
Cheng Liu
Su Yan
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/031892 external-priority patent/WO2012135854A2/en
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of TN2013000387A1 publication Critical patent/TN2013000387A1/en

Links

Abstract

The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.
TNP2013000387A 2011-05-31 2013-09-26 T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 TN2013000387A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161491392P 2011-05-31 2011-05-31
PCT/US2012/031892 WO2012135854A2 (en) 2011-04-01 2012-04-02 Antibodies to cytosolic peptides

Publications (1)

Publication Number Publication Date
TN2013000387A1 true TN2013000387A1 (en) 2015-01-20

Family

ID=52395383

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000387A TN2013000387A1 (en) 2011-05-31 2013-09-26 T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2

Country Status (1)

Country Link
TN (1) TN2013000387A1 (en)

Similar Documents

Publication Publication Date Title
MX2013011363A (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2.
WO2016191246A3 (en) T cell receptor-like antibodies specific for a prame peptide
PH12019500603A1 (en) Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
MX2020004410A (en) Antibody compositions for tumor treatment.
MX369148B (en) Kir3dl2 binding agents.
MX2018010331A (en) Vegf/dll4 binding agents and uses thereof.
TN2014000148A1 (en) Antigen binding protein and its use as addressing product for the treatment of cancer
BR112012021941A2 (en) Therapeutic dll4 binding proteins
MX2013011706A (en) Novel egfr binding proteins.
IN2014MN00873A (en)
UA95068C2 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
EA201390328A1 (en) NEW ANTIGENS-BINDING PROTEINS
IN2014CN03936A (en)
MX2009009450A (en) He4 monoclonal antibodies and methods for their use.
EP2579895A4 (en) Anti-vegf antibodies and uses thereof
UA102891C2 (en) Fully human antibodies specific to cadm1
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
UA114108C2 (en) Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
UA99602C2 (en) Antibody that specifically binds to jam-a, capable of inhibiting the proliferation of tumor cells
NZ709828A (en) Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
MX2020010104A (en) Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates.
MX2021003673A (en) Anti-human vsig4 antibodies and uses thereof.
BR112018008983A2 (en) asct2-specific binding molecules and their uses
TN2013000387A1 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
HK1116198A1 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth